Promising Company of the Center for Innovative Startups in the Health Industry — Shaping the Future with Innovation DNA

■ Pain Relief and Functional Improvement… Published in the International Journal Journal of Medical Internet Research (JMIR)

□ Beyond Medicine Co., Ltd. (CEO: Dae-Hyun Kim), a company supported by the Center for Innovative Startups in the Health Industry, announced that a clinical study on Clickless, the first digital therapeutic designated as an innovative medical device in the Korean dental field for temporomandibular disorders (TMD), has been published in the world-renowned digital health journal Journal of Medical Internet Research (JMIR).

□ The research team led by Professor Sang-Yoon Park from Hallym University Sacred Heart Hospital published a paper titled “Evaluating the Efficacy of a Digital Therapeutic Intervention for Temporomandibular Disorders: Multicenter, Randomized, Sham-Controlled Trial,” which assessed the clinical efficacy of Beyond Medicine’s digital therapeutic Clickless.

○ This study serves as an international validation of the clinical efficacy of Clickless for treating temporomandibular disorders, demonstrating that the Clickless group showed statistically significant improvement in both pain relief and functional recovery compared to the control group.

□ Conducted between June 2024 and June 2025 at two hospitals (Hallym University Sacred Heart Hospital and Hallym University Dongtan Sacred Heart Hospital), the study involved 102 patients diagnosed with TMD. Participants were randomly assigned to either the Clickless app treatment group (50 participants) or the sham (placebo) app group (52 participants). The research team compared and analyzed the symptom improvement between the two groups.

○ Participants in the Clickless group used the app daily for 5–10 minutes to engage in jaw relaxation exercises, mindfulness practices, behavior tracking, educational modules, and data-driven feedback sessions. The sham app group received an identical-looking app without any therapeutic functionality. Both groups continued their existing treatments throughout the trial period.

○ After six weeks, the Clickless group showed an average reduction of 33.6 points in pain intensity — more than three times greater than the 9.9-point reduction observed in the sham app group. Additionally, significant 3–5× improvements were observed in jaw mobility, joint restriction tests, and self-reported surveys. In particular, oral bad habit indices — a key factor in TMD — improved by more than fivefold.

□ The research team noted, “Consistent improvement in both objective measures and patient perception suggests that digital therapeutics can support both physical and psychological recovery.” They further explained, “The structured cognitive behavioral therapy (CBT) modules and real-time feedback system within Clickless enhanced patient engagement and self-management, leading to faster and more sustained pain reduction compared to conventional treatments.”

○ The researchers emphasized, “Whereas conventional treatments often required several weeks for symptom relief, patients who used Clickless alongside standard care experienced both pain reduction and functional recovery within a short period — a finding of great clinical significance.” They added, “Digital therapeutics serve as a practical and scalable tool that bridges the gap between hospital visits, empowering patients to manage their conditions independently. Particularly for TMD, which involves chronic pain and behavioral factors, this represents a novel approach capable of delivering standardized interventions even in remote settings.”

□ CEO Dae-Hyun Kim of Beyond Medicine stated, “This study provides objective clinical evidence of Clickless’s medical efficacy, marking a major milestone for the integration of digital therapeutics into the dental field in Korea. Based on these evidence-based R&D achievements, we will continue to enhance clinical applicability and deliver tangible therapeutic benefits to both clinicians and patients.”

□ As a promising startup recognized by the Center for Innovative Startups in the Health Industry, Beyond Medicine has been selected for the Deep Tech Track (2025) of the Startup Leap Package Program supported by the Korea Health Industry Development Institute (KHIDI). The company continues to receive full-cycle commercialization support, including mentoring and technology promotion, as well as concurrent support under the Technology Evaluation–Commercialization Linkage Program and the Health Industry Patent Strategy and Regulatory Consulting Program.

Inquiries:

• Prof. Sang-Yoon Park, Oral and Maxillofacial Surgery, Hallym University Sacred Heart Hospital (psypjy0112@naver.com)

Exhibitor Data Sheet